Amphotericin B: Is a Lipid‐Formulation Gold Standard Feasible?
Open Access
- 15 January 2004
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 38 (2) , 304-305
- https://doi.org/10.1086/380844
Abstract
Sir—We read with interest the article by Ostrosky-Zeichner et al. [1] proposing that lipid-based formulations of amphotericin B (LFABs) replace amphotericin B deoxycholate (AmBD) as the gold standard for treatment of most invasive mycoses. On the basis of a review of comparative efficacy, toxicity, and cost, we believe AmBD remains a viable first-line agent.Keywords
This publication has 8 references indexed in Scilit:
- Amphotericin B: Time for a New "Gold Standard"Clinical Infectious Diseases, 2003
- Safety and Efficacy of Liposomal Amphotericin B Compared with Conventional Amphotericin B for Induction Therapy of Histoplasmosis in Patients with AIDSAnnals of Internal Medicine, 2002
- Pharmacoeconomic Analysis of Liposomal Amphotericin B Versus Conventional Amphotericin B in the Empirical Treatment of Persistently Febrile Neutropenic PatientsJournal of Clinical Oncology, 2000
- Amphotericin B-Induced Nephrotoxicity: A ReviewJournal of Chemotherapy, 2000
- Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and NeutropeniaNew England Journal of Medicine, 1999
- Risk factors for amphotericin B- induced nephrotoxicityJournal of Antimicrobial Chemotherapy, 1999
- Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitisAIDS, 1997
- Amphotericin B Blunts Erythropoietin Response to AnemiaThe Journal of Infectious Diseases, 1990